The review of biomarkers for sepsis aims to identify or rule out sepsis, guide therapy, and assess patient response. A comprehensive search of the PubMed database using the keywords "sepsis" and "biomarker" identified 3370 references covering 178 different biomarkers. Most biomarkers were clinically tested, primarily as prognostic markers, with few used for diagnosis. None has sufficient specificity or sensitivity for routine clinical use. Procalcitonin (PCT) and C-reactive protein (CRP) are the most widely used, but they have limited ability to distinguish sepsis from other inflammatory conditions or predict outcomes. The complexity of sepsis, involving multiple mediators and pathophysiological mechanisms, makes it unlikely that a single ideal biomarker will be found. Combining several biomarkers may improve effectiveness, but further evaluation is needed.The review of biomarkers for sepsis aims to identify or rule out sepsis, guide therapy, and assess patient response. A comprehensive search of the PubMed database using the keywords "sepsis" and "biomarker" identified 3370 references covering 178 different biomarkers. Most biomarkers were clinically tested, primarily as prognostic markers, with few used for diagnosis. None has sufficient specificity or sensitivity for routine clinical use. Procalcitonin (PCT) and C-reactive protein (CRP) are the most widely used, but they have limited ability to distinguish sepsis from other inflammatory conditions or predict outcomes. The complexity of sepsis, involving multiple mediators and pathophysiological mechanisms, makes it unlikely that a single ideal biomarker will be found. Combining several biomarkers may improve effectiveness, but further evaluation is needed.